Aggressive management of diabetic ketoacidosis in the emergency department (ED) can quickly correct associated hyperglycemia and metabolic acidosis.
Read More »Issue 121 Item 3 Missed ZZZ’s, More Diabetes?
One-third of the population sleeps 6.5 or fewer hours, far less than the 8 hours that many sleep specialists recommend, which can impair the body’s processing of glucose.
Read More »Issue 122 Item 3 Partners of Type 2 Diabetics Experience Depression, Anxiety As
The partners of patients with type 2 diabetes experience at least as much depression and anxiety as the diabetic patients themselves, especially if they are female.
Read More »Issue 123 Item 4 Sildenafil Improves Endothelial Function in Type 2 Diabetics
In patients with type 2 diabetes, sildenafil (Viagra) improves flow-mediated dilatation (FMD), an index of nitric oxide-dependent endothelial function, according to a recent report.
Read More »Issue 124 Item 3 New Insulin Seen as Key to Saving Millions of Patients with Dia
Nanomized Insulin made of smaller particles and reduces number of daily injections.
Read More »Issue 125 Item 3 Older Women With Diabetes Have a Higher Risk of Falls
Can improving diabetes treatment reduce the risk for falls?
Read More »Issue 126 Item 3 Simvastatin Protects against Endothelial Dysfunction in Type 2
Simvastatin minimizes oxidative stress and endothelial dysfunction brought on by the cumulative effects of postprandial hypertriglyceridemia and hyperglycemia seen in type 2 diabetics.
Read More »Kidney Disease Is Related to How Well Insulin Works
Insulin resistance, a condition commonly associated with the development of type 2 diabetes, is likely a major cause of kidney disease, or nephropathy, in people with type 1 diabetes.
Read More »Issue 122 Item 2 Insulin Resistance Best Predictor of Diabetic Nephropathy
Insulin resistance is most predictive of diabetic nephropathy in the long-term, according to the results of a 10-year prospective study published in the September issue of Kidney International.
Read More »Eli Lilly Cuts Deal for the Rights to a New Diabetes Drug from
Eli Lilly & Company will pay up to $325 million to Amylin Pharmaceuticals, a biotechnology company based in San Diego, for the rights to a potentially promising treatment for diabetes.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.